Lantheus Holdings (LNTH) Cash & Current Investments (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Cash & Current Investments came in at $498.6 million in Q1 2026, down 46.88% year-on-year from $938.5 million in Q1 2025, and up 38.83% on a QoQ basis from $359.1 million in Q4 2025.
Lantheus Holdings (LNTH) Cash & Current Investments (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Cash & Current Investments data on file, last reported at $498.6 million in Q1 2026.
- On a quarterly basis, Cash & Current Investments fell 46.88% year-over-year to $498.6 million in Q1 2026; TTM through Mar 2026 was $498.6 million, a 46.88% decrease from a year earlier, with the FY2025 full-year figure at $359.1 million, down 60.66% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $498.6 million, up from $359.1 million in the prior quarter.
- Over the last five years, Cash & Current Investments for LNTH reached as high as $938.5 million in Q1 2025 and fell as low as $105.4 million in Q1 2022.
- Historically, Cash & Current Investments has averaged $546.5 million across 5 years, with a median of $498.6 million in 2026.
- Across the five-year window, Cash & Current Investments surged 346.93% in 2023 and tumbled 60.66% in 2025, its largest moves.
- Year by year, Cash & Current Investments stood at $415.7 million in 2022, then jumped by 71.7% to $713.7 million in 2023, then advanced by 27.91% to $912.8 million in 2024, then tumbled by 60.66% to $359.1 million in 2025, then soared by 38.83% to $498.6 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $498.6 million in Q1 2026, $359.1 million in Q4 2025, and $382.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 2.15 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 498.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 498.58 Mn |
| Dec 31, 2025 | 359.12 Mn |
| Sep 30, 2025 | 382.01 Mn |
| Jun 30, 2025 | 695.57 Mn |
| Mar 31, 2025 | 938.53 Mn |
| Dec 31, 2024 | 912.81 Mn |
| Sep 30, 2024 | 866.39 Mn |
| Jun 30, 2024 | 757.02 Mn |
| Mar 31, 2024 | 718.28 Mn |
| Dec 31, 2023 | 713.66 Mn |
| Sep 30, 2023 | 614.13 Mn |
| Jun 30, 2023 | 414.08 Mn |
| Mar 31, 2023 | 470.86 Mn |
| Dec 31, 2022 | 415.65 Mn |
| Sep 30, 2022 | 257.26 Mn |
| Jun 30, 2022 | 171.43 Mn |
| Mar 31, 2022 | 105.36 Mn |
| Dec 31, 2021 | 98.51 Mn |
| Sep 30, 2021 | 91.48 Mn |
| Jun 30, 2021 | 91.50 Mn |